ArchiMed's MED II fund fully invested following Cube buyout

Cube co-founders and managing directors Barbara Maertens, Jan Kubicek and Roland Fabis will remain significant shareholders alongside ArchiMed, maintaining their leadership positions at Cube.

Cube is ArchiMed's latest investment in Germany, following the acquisition last December of Zyto Group, a developer of precision cancer diagnostics.

ArchiMed said it would aim to help expand sales in the US and broaden Cube's product and service offering, organically and via acquisitions.

Cube is the last platform investment for the GP's MED II fund, which closed on its EUR 315m hard-cap in 2017 after four months on the road. The fund invested in European businesses with an equity ticket ranging between EUR 5m-50m, and aimed to complete about 12 transactions.

ArchiMed recently held a first and final close for the vehicle's successor, MED III, on its hard-cap of EUR 650m in less than two months. The first fund in that strategy, 2014-vintage MED I, has distributed more than 4x invested capital to LPs and has a total return in excess of 6x invested capital, the firm said in a statement.

Company
Founded in 2012, Cube has developed proprietary methods and products to provide high-purity, stable-membrane proteins for drug discovery. Membrane proteins are found across the surface of cells, playing a key role as receptors for drugs, but are difficult to extract without loss of native functionality, according to the company. Cube claims that it can achieve stable extraction of these proteins, aiding successful structure determination and effective drug discovery.

People
ArchiMed – Denis Ribon (managing partner); Klaus Maleck (operating partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Archimed
• Buy-and-build
• Germany